Lumify™ (brimonidine) – New over-the-counter drug approval

- On December 22, 2017, Bausch and Lomb announced the FDA approval of Lumify (brimonidine) 0.025% ophthalmic solution, to relieve redness of the eye due to minor eye irritations.

- Lumify is the first over-the-counter (OTC) eye drop developed with low-dose brimonidine.

- Brimonidine is also available as ophthalmic prescription medications in higher doses as follows: 0.15% solution, 0.2% solution, Alphagan® P 0.1% and 0.15% solution, 0.2% suspension in combination with brinzolamide 1% (Simbrinza™), and 0.2% solution in combination with timolol 0.5% (Combigan®).

  - These prescription strength brimonidine products are indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

- Warnings of Lumify include for external use only; do not use if solution changes color or becomes cloudy; and stop use and consult a doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, condition worsens or persists for more than 3 days.

- The recommended dosage of Lumify in adults and children ≥ 5 years is one drop into the affected eye(s) every 6 - 8 hours.

  - Lumify should not be used more than four times daily.
  - Contact lenses should be removed before instilling Lumify. Lenses may be re-inserted 10 minutes after instilling Lumify.
  - If other ophthalmic products are being used, wait 5 minutes between using each product.

- Bausch and Lomb plans to launch Lumify in the second quarter of 2018.